Sonoma Pharmaceuticals, Inc. (SNOA) News
Filter SNOA News Items
SNOA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SNOA News From Around the Web
Below are the latest news stories about SONOMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SNOA as an investment opportunity.
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical DevicesSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and ... |
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain StockIf you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. |
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United StatesBOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... |
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care HydrogelBOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... |
Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagSonoma Pharmaceuticals ( NASDAQ:SNOA ) Second Quarter 2025 Results Key Financial Results Revenue: US$3.58m (up 31% from... |
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial ResultsRevenue increased 31% for the quarter compared to same period prior year Positive cash flows from operations of $0.35 million for the quarter Net loss improved 59% for the quarter compared to same period prior year Net loss per share improved 90% ... |
Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in DüsseldorfBOULDER, CO / ACCESSWIRE / October 31, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... |
Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in CanadaBOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... |
Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor ConferencesBOULDER, CO / ACCESSWIRE / October 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... |
Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleBOULDER, CO / ACCESSWIRE / September 19, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... |